Dr. David Agus

We don't have a near-term readout. And so it's been very difficult to get compliance and to get people to do them. There's a new generation of statin equivalents, drugs that lower inflammation and cholesterol that came out that literally are a shot once a year. It's a technology called siRNA. They're FDA approved, and they could downregulate the pathways to lower cholesterol a year at a time.

We don't have a near-term readout. And so it's been very difficult to get compliance and to get people to do them. There's a new generation of statin equivalents, drugs that lower inflammation and cholesterol that came out that literally are a shot once a year. It's a technology called siRNA. They're FDA approved, and they could downregulate the pathways to lower cholesterol a year at a time.

Obviously, dramatically helps with the compliance, but that's been part of the problem.

Obviously, dramatically helps with the compliance, but that's been part of the problem.

Obviously, dramatically helps with the compliance, but that's been part of the problem.

Well, listen, aspirin's 2000 years old. In three large randomized studies with over 100,000 people, what it did was reduce the overall death rate, not the incidence, the death rate of cancer by 30%, heart disease by 22%, and stroke by 17%.

Well, listen, aspirin's 2000 years old. In three large randomized studies with over 100,000 people, what it did was reduce the overall death rate, not the incidence, the death rate of cancer by 30%, heart disease by 22%, and stroke by 17%.

Well, listen, aspirin's 2000 years old. In three large randomized studies with over 100,000 people, what it did was reduce the overall death rate, not the incidence, the death rate of cancer by 30%, heart disease by 22%, and stroke by 17%.

and obviously there was a benefit there there's been newer data out showing that if you take aspirin for four years starting at a later age that there was no benefit in increased fleets and there's no question there's increased please but you need to take it

and obviously there was a benefit there there's been newer data out showing that if you take aspirin for four years starting at a later age that there was no benefit in increased fleets and there's no question there's increased please but you need to take it

and obviously there was a benefit there there's been newer data out showing that if you take aspirin for four years starting at a later age that there was no benefit in increased fleets and there's no question there's increased please but you need to take it

for six years to see the benefit on cancer and people who don't start aspirin to really late there's normally a reason for that and so if you look at the ground data it's very powerful not everybody should be on it but it's discussion to have with your doctor hey listen if you have a family history of pancreatic cancer or colon cancer you get about a 50 reduction in those cancers by taking a baby aspirin every day but you got to take it earlier in life you can't wait till you're 80.

for six years to see the benefit on cancer and people who don't start aspirin to really late there's normally a reason for that and so if you look at the ground data it's very powerful not everybody should be on it but it's discussion to have with your doctor hey listen if you have a family history of pancreatic cancer or colon cancer you get about a 50 reduction in those cancers by taking a baby aspirin every day but you got to take it earlier in life you can't wait till you're 80.

for six years to see the benefit on cancer and people who don't start aspirin to really late there's normally a reason for that and so if you look at the ground data it's very powerful not everybody should be on it but it's discussion to have with your doctor hey listen if you have a family history of pancreatic cancer or colon cancer you get about a 50 reduction in those cancers by taking a baby aspirin every day but you got to take it earlier in life you can't wait till you're 80.

Yeah, you got to start earlier, and that's where the real benefit is, and the risk of bleeding is much slower. Listen, an 89-year-old, they fall a lot, so risk of bleeding is high. A 40-, 50-, 60-year-old don't, and it's different. That being said, if aspirin is 2,000 years old, why don't we have a Gen 2.0 of aspirin that has the anti-inflammatory parts but doesn't have the bleeding parts?

Yeah, you got to start earlier, and that's where the real benefit is, and the risk of bleeding is much slower. Listen, an 89-year-old, they fall a lot, so risk of bleeding is high. A 40-, 50-, 60-year-old don't, and it's different. That being said, if aspirin is 2,000 years old, why don't we have a Gen 2.0 of aspirin that has the anti-inflammatory parts but doesn't have the bleeding parts?

Yeah, you got to start earlier, and that's where the real benefit is, and the risk of bleeding is much slower. Listen, an 89-year-old, they fall a lot, so risk of bleeding is high. A 40-, 50-, 60-year-old don't, and it's different. That being said, if aspirin is 2,000 years old, why don't we have a Gen 2.0 of aspirin that has the anti-inflammatory parts but doesn't have the bleeding parts?

Unfortunately, there's no patent on aspirin, so there's been no pharma working on this. I wish they would.

Unfortunately, there's no patent on aspirin, so there's been no pharma working on this. I wish they would.

Unfortunately, there's no patent on aspirin, so there's been no pharma working on this. I wish they would.